RegenPRP™ - HA

Class III CE certified Medical Devices
under Regulation (EU) 2017/745.
Regen Lab SA is an ISO 13485:2016

and MDSAP certified medical device manufacturer

 

RegenPRP™ in combination with HA

1.1 – Platelet Rich Plasma

RegenPRP™: the platelet concentrate prepared with this Regenlab® technology provides an autologous reservoir of growth factors.

  • Proven role in the healing of tissues, with key roles in cell migration, proliferation and differentiation
  • Mechanism of action comprises anti-inflammatory activity and activation of cell-signalling cascades
  • Key role in the synthesis of new extracellular matrix for tissue regeneration

1.2 – Hyaluronic Acid

Hyaluronic acid is a major component of synovial fluid contributing to joint homeostasis.

  • 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in OA patients.
  • Plays a major role in viscosupplementation and pain relief in OA.4
  • The network of HA chains generates an ideal cell-friendly matrix when combined with PRP.5

Breaking the vicious cycle of knee osteoarthritis

SYNERGISTIC ACTION

Pain Relief

Inflammation Reduction

De Novo HA Synthesis

Cell Moduclation

R
R
R
R

SYNEGISTIC ACTION

Pain Relief

Inflammation Reduction

Cell Moduclation

De Novo HA Synthesis

HA

R
R
R
R

PRP

R
R
R
R
$

Hyaluronic acid improves the activity of several molecules contained in platelet-rich plasma to provide additional bene  ts to OA patients.1

Both PRP and HA have been extensively used not only to reduce clinical symptoms, but also to slow down OA progression.5,7

$

When PRP and HA are used in combination these effects are enhanced and prolonged. HA creates a bioactive sca  old in which the platelets progressively release their growth factors. RegenPRPdoes not negatively affect the mechanical, elastic or viscous properties of HA.1

Cellular Matrix is a unique, regulatory approved, patented technology that allows the safe, closed-circuit preparation of a cell-friendly PRP-HA network in which platelets and plasma components are retained.

%

Platelet recovery

%

Granulocyte depletion

%

Red blood cell depletion

Hyaluronic acid improves the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients.*

Bibliography

1. Abate M. et al. E  cacy and safety pro  le of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results). Eur J Orthop Surg Traumatol 2015 Dec;25(8):1321-6.

2. Fountain, J. H. and S. L. Lappin (2019). Physiology, Platelet, StatPearls Publishing, Treasure Island (FL).

3. Mathew, J. and M. Varacallo (2019). Physiology, Blood Plasma, StatPearls Publishing, Treasure Island (FL).

4. Oeding, J. F., N. H. Varady, F. W. Fearington, A. Pareek, S. M. Strickland, B. U. Nwachukwu, C. L. Camp and A. J. Krych (2024). «Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials.» Am J Sports Med: 3635465231224463

5. Huskisson, E. C., and S. Donnelly. «Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee.» [In eng]. Rheumatology (Oxford) 38, no. 7 (Jul 1999): 602-7.

6. Smith J.D. et al. Improved growth factor directed vascularisation into fibrin constructs through inclusion of additional extracellular molecules. Microvasc Res. 2007;73(2):84-94.

7. Chen CPC, Cheng CH, Hsu CC, Lin HC, Tsai YR, Chen JL. The in  uence of platelet rich plasma on synovial fluid volumes, protein concentrations, and severity of pain in patients with knee osteoarthritis. Experimental gerontology 2017;93:68-72.

8. Renevier, J. L., et al. «Cellular Matrix PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up.» Int. J. Clin. Rheumatol. 2018;13(4):230-8

9. Barac, B., et al. (The new treatment approach in knee osteoarthritis: Effcacy of cellular matrix combination of platelet rich plasma with hyaluronic acid versus two different types of hyaluronic acid (HA). Int. J. Clin. Rheumatol. 2018;13(5):289-95

Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufa​cturing of high-quality medical devices.

Copyright © 2024 All rights reserved.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ est un traitement médical qui utilise le plasma riche en plaquettes provenant du sang du patient pour améliorer et la régénération tissulaire.

RegenPRP™ - HA

Cellular Matrix® est un traitement innovant combinant le plasma riche en plaquettes (PRP) et l'acide hyaluronique pour améliorer la régénération tissulaire et la guérison.

RegenPRP™ - ATS

RegenPRP™ combiné avec ATS (Autologous Thrombin Serum) est une approche avancée pour la régénération tissulaire qui utilise le plasma riche en plaquettes (PRP) enrichi en thrombine autologue pour maximiser les effets de guérison.

RegenExtracell®

RegenExtracell est un traitement innovant axé sur la régénération tissulaire qui utilise une matrice extracellulaire enrichie en plasma riche en plaquettes (PRP).

Hyaluronic Acid

L'acide hyaluronique est une substance naturellement présente dans le corps humain, particulièrement dans la peau, les articulations et les yeux.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.

Safety & Privacy policies

WEBSITE PRIVACY NOTICE

We recommend you to acquaint yourself with the full content of our Privacy Policy.